Document is current
Any future updates will be listed below
-
Authors
Mannino, David https://orcid.org/0000-0003-3646-7828
DiRocco, Kristi https://orcid.org/0009-0006-2988-5684
Germain, Guillaume https://orcid.org/0000-0002-4525-7673
Laliberté, François https://orcid.org/0000-0003-2601-6214
Noorduyn, Stephen G. https://orcid.org/0000-0002-5936-5579
Urosevic, Ana
Paczkowski, Rosirene https://orcid.org/0009-0001-7151-4311
-
Funding
Funding for this research was provided by:
GSK
- License Information
-
More Information
Article History
Received: 20 June 2024
Accepted: 12 September 2024
First Online: 25 October 2024
Declarations
:
: David Mannino is a consultant for AstraZeneca, the COPD Foundation, Genentech, GSK, Regeneron, and Up-to-Date. David Mannino is also an expert witness on behalf of people suing the tobacco and vaping industries. Kristi DiRocco, Stephen G. Noorduyn, and Rosirene Paczkowski are employed by GSK and/or hold financial equities in GSK. Stephen G. Noorduyn is also a PhD candidate at McMaster University. Guillaume Germain and François Laliberté are employees of Groupe d’analyse, Ltée, which received funding from GSK to conduct this study. Ana Urosevic was an employee of Groupe d’analyse, Ltée, at the time of the study. Current affiliation details for Ana Urosevic: Thumbtack, San Francisco, CA, USA.
: As this was an analysis of claims data, institutional review board (IRB) approval was not required. Per Title 45 of the Code of Federal Regulations, Part 46 (), the administrative claims data analysis of our study was exempt from the IRB review as it was a retrospective analysis of existing data (hence no patient intervention or interaction), and no patient-identifiable information was included in the claims dataset.
